Home > Insider Trading > Filing (0000899243-22-004197)

Filing Details

Accession Number:: 0000899243-22-004197
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2022-02-02 18:00:17
Reporting Period:: 2022-01-31

Accepted Time:: 2022-02-02 18:00:17
Original Submission Date:: 2021-07-07
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1745999	Beam Therapeutics Inc.	BEAM	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1786304	M. John Evans	C/O Beam Therapeutics Inc. 238 Main Street Cambridge MA 02142	Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-11-16	12,000	$0.00	968,825	No	5	G	Direct
Common Stock	Disposition	2022-01-31	801	$63.79	968,024	No	4	S	Direct
Common Stock	Disposition	2022-01-31	2,172	$64.47	965,852	No	4	S	Direct
Common Stock	Disposition	2022-01-31	3,177	$65.49	962,675	No	4	S	Direct
Common Stock	Disposition	2022-01-31	6,337	$66.55	956,338	No	4	S	Direct
Common Stock	Disposition	2022-01-31	13,535	$67.44	942,803	No	4	S	Direct
Common Stock	Disposition	2022-01-31	3,978	$68.15	938,825	No	4	S	Direct
Common Stock	Acquisiton	2022-01-31	100,000	$1.03	1,038,825	No	4	M	Direct
Common Stock	Disposition	2022-01-31	300	$63.45	182,700	No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust
Common Stock	Disposition	2022-01-31	1,615	$64.46	181,085	No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust
Common Stock	Disposition	2022-01-31	1,900	$65.55	179,185	No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust
Common Stock	Disposition	2022-01-31	4,105	$66.48	175,080	No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust
Common Stock	Disposition	2022-01-31	9,408	$67.43	165,672	No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust
Common Stock	Disposition	2022-01-31	2,672	$68.16	163,000	No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	5	G	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust
No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust
No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust
No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust
No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust
No	4	S	Indirect	By John M. Evans, III 2018 Irrevocable Trust

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2022-01-31	100,000	$0.00	100,000	$1.03
Common Stock	Stock Option (Right to Buy)	Acquisiton	2022-01-31	112,500	$0.00	112,500	$69.21

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
284,345		2028-07-13	No	4	M	Direct
112,500		2032-01-31	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	980,825	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option (Right to Buy)	$1.03		2028-07-13	0	384,345	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2028-07-13	0	384,345	Direct

Footnotes

On each of July 7, 2021 and October 6, 2021, the reporting person filed a Form 4 which inadvertently reported an exercise of stock options in connection with certain sales of common stock. In fact, the reporting person did not exercise any stock options in connection with the sales reported on such Forms 4. Accordingly, the first line of each of Tables 1 and 2 of this Form 4 reflects the corrected number of securities beneficially owned by the reporting person prior to the transactions reported herein.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $63.60 to $63.96, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.21 to $64.50, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.20 to $65.99, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.09 to $66.94, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.00 to $67.99, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $68.00 to $68.60, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $63.26 to $63.58, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.17 to $64.50, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.20 to $65.99, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.00 to $66.94, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.00 to $67.99, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $68.00 to $68.60, inclusive.
The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested.
The option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the reporting person's continued service with BEAM through each vesting date.